Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention ; volume:7 ; number:1 ; day:25 ; month:10 ; year:2023 ; pages:1-12 ; date:12.2023
npj precision oncology ; 7, Heft 1 (25.10.2023), 1-12, 12.2023
- Creator
-
Lee, Sang Beom
Pan, Jing
Xiong, Donghai
Palen, Katie
Johnson, Bryon
Lubet, Ronald A.
Shoemaker, Robert H.
Green, Jeffrey E.
Fernando, Romaine Ingrid
Sei, Shizuko
You, Ming
Wang, Yian
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41698-023-00461-1
- URN
-
urn:nbn:de:101:1-2024020112340880312694
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lee, Sang Beom
- Pan, Jing
- Xiong, Donghai
- Palen, Katie
- Johnson, Bryon
- Lubet, Ronald A.
- Shoemaker, Robert H.
- Green, Jeffrey E.
- Fernando, Romaine Ingrid
- Sei, Shizuko
- You, Ming
- Wang, Yian
- SpringerLink (Online service)
Other Objects (12)
New Vaccine Therapy for Triple-Negative Breast Cancer
Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer
Targeting a cell state common to triple‐negative breast cancers
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer
Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer
Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer
Characterizing triple-negative breast cancer tumors
Triple-Negative Breast Cancer: Multimodality Appearance
New Vaccine Therapy for Triple-Negative Breast Cancer
Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer
Targeting a cell state common to triple‐negative breast cancers
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer
Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer
Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer
Characterizing triple-negative breast cancer tumors
Triple-Negative Breast Cancer: Multimodality Appearance
New Vaccine Therapy for Triple-Negative Breast Cancer
Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer
Targeting a cell state common to triple‐negative breast cancers
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer
Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer
Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer
Characterizing triple-negative breast cancer tumors